What is Lenire? Comparing Our Proven Tinnitus Retraining Therapy to a New Product
Tinnitus is a common condition where an individual experiences ringing or buzzing in the ears. It is estimated that around 15-20% of people worldwide suffer from tinnitus at some point in their lives. The newest claim to tinnitus treatment, Lenire technology, has gained significant attention recently. In this article, we will discuss the Lenire technology, the studies involved, FDA approval, and how it compares to existing, successful tinnitus treatment.
About Lenire Devices
Lenire, developed by Neuromod Devices, is a therapeutic device designed to alleviate the symptoms of tinnitus. The device utilizes electrical stimulation delivered to the tongue and the skin behind the ears to disrupt the neural patterns associated with tinnitus. By customizing the electrical impulses based on the individual’s tinnitus symptoms, Lenire aims to modulate the neural activity in the auditory system, reducing the perception of tinnitus. Limited clinical trials show some potential for short term benefit – but have yet to prove long term viability for repelling chronic tinnitus symptoms.
Our TRT study was done over a period of 10 years, with significant long term benefits.
How Effective are Lenire Devices to Alleviate Tinnitus Symptoms?
In a recent study, researchers investigated the effectiveness of bimodal stimulation for managing subjective tinnitus in individuals between the ages of 18 to 70 years old, with tinnitus duration ranging from 3 months to 10 years. Candidates were required to have a maximum hearing loss (HL) of 40 dB HL, and the treatment involved bimodal stimulation using both tongue and ear stimulation with pure tones ranging from 500 to 8K Hz, without any background wideband noise. The amplitude of the pure tones was adjustable, with a maximum of 70 dB for normal hearing and 90 dB for severe hearing loss. The study utilized Tinnitus Handicap and Tinnitus Functional Index as evaluation measures.
We treat many people with normal hearing. Lenire requirements are to have a hearing loss.
After 6 weeks of treatment, tinnitus symptoms were observed again, and the effects of the treatment appeared to be sustainable up to 12 months for select patients. Out of 462 potential participants, 194 were randomized and 191 completed the enrollment and device fitting.
Our study was based on 1,000 tinnitus patients.
In March 2023, Neuromod Devices Ltd. received FDA De Novo classification for the Lenire technology, a bimodal neuromodulation device intended for the treatment of chronic tinnitus. This regulatory pathway allows Neuromod Devices to market and sell Lenire in the US. Only a select number of clinics across the nation currently offer this specific treatment option as opposed to clinics offering current methods of proven tinnitus retraining therapy (TRT) nationwide. This is because Lenire is still in a trial period to test things out.
How Does it Compare to Existing Treatments for Tinnitus?
Existing treatments for tinnitus include cognitive-behavioral therapy, sound therapy, and medication for inter-related conditions. Cognitive-behavioral therapy involves counseling and education to help individuals with tinnitus manage their symptoms. Sound therapy utilizes sounds not to mask tinnitus, but rather retrain the misguided auditory path in the brain associated with tinnitus symptoms. Hope Hearing & Tinnitus Center offers cutting edge tinnitus retraining utilizing proven sound therapy methods backed by many clinical studies.
Medications, such as antidepressants and anti-anxiety drugs, are sometimes prescribed to manage the emotional distress associated with tinnitus – but not the symptoms directly. There are currently no medications available with clinical results associated with improvement of tinnitus symptoms.
Lenire’s approach to tinnitus is this bimodal therapy that has to be done up to an hour daily. For many of those suffering from tinnitus this can make tinnitus even more of a focal point and cause increasing anxiety and fixation.
Tinnitus is a challenging condition to manage, and the Lenire technology seeks to provide an additional approach to its treatment. While it has achieved FDA De Novo approval, clinical studies are still limited – as is treatment availability in the United States as of this writing.
To learn more about proven clinical treatment for tinnitus through sound therapy retraining, contact Hope Hearing & Tinnitus Center with locations in Southlake, TX and Hiawatha, IA. The current success rate for patients using TRT in association with Dr. Beki Kellogg’s diagnoses and treatment plan is above 80%. The doctors at Hope Hearing look forward to monitoring the long term viability of Lenire technology as more patients report results compared to the high success rate of existing treatment options. It is the goal of the clinic to provide the best treatment options possible for anyone experiencing the chronic ringing or buzzing of tinnitus!